UNSPSC 51371601: Tramadol

This classification denotes an analgesic agent with the molecular formula C16H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 39J1LGJ30J, chemically known as cyclohexanol, 2-((dimethylamino)methyl)-1-(m-methoxyphenyl)- but generally known as tramadol, which bears US NIH Compound Identifier 33741. European Medicines Agency schedules Tramadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11210MIG.

UNSPSC 51371601 Tramadol is a Commodity code representing opioid pharmaceuticals, but recent state and local activity under this code shows minimal direct procurement of tramadol itself; instead, issuing bodies are using the code to solicit complementary pharmaceutical and controlled-substance management products and services. Seminole County, Florida solicited naloxone and safe drug deactivation systems through an IFB; Texas Health and Human Services Commission issued an RFI on direct-to-manufacturer prescription programs; and Minnesota's multistate cooperative purchasing alliance (MMCAP) sought generic multi-source pharmaceuticals and OTC products through an RFP. The scope of work spans community health initiatives, pharmacy benefit management, and controlled-substance harm-reduction logistics rather than tramadol distribution alone.

The issuing bodies include county governments (Seminole County), state health agencies (Texas HHS), and multistate cooperative purchasing vehicles (MMCAP, administered by the Minnesota Department of Administration). Recent activity appears concentrated in Florida, Texas, and Minnesota, with MMCAP's cooperative extending to Oregon. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, due July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building in Sanford; Texas HHS's RFI (HHS0017013) on direct-to-manufacturer prescriptions, posted April 3, 2026; and MMCAP's RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and awards effective July 1, 2026. The code's practical use by state and local procurement offices reflects broader pharmaceutical supply-chain and harm-reduction priorities rather than tramadol-specific sourcing.